<div id="readability-page-1"><p>Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Tuesday, December 23rd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.56 per share for the year, up from their prior forecast of $0.51. HC Wainwright currently has a &#34;Buy&#34; rating and a $10.00 target price on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share.</p><p>Several other brokerages also recently weighed in on SVRA. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Savara in a report on Wednesday, October 8th. UBS Group  set a $10.00 price objective on Savara in a research report on Tuesday. Guggenheim  reiterated a &#34;buy&#34; rating on shares of Savara in a research report on Tuesday. Wells Fargo &amp; Company boosted their price target on Savara from $7.00 to $9.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, December 18th. Finally, Oppenheimer  set a $10.00 price target on Savara in a research note on Tuesday. One research analyst  has rated the stock with a Strong Buy rating, seven have given a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $9.13.</p><p><b>Read Our Latest Stock Analysis on SVRA</b></p><h2>Savara Stock Performance</h2><p>Shares of NASDAQ SVRA opened at $6.44 on Wednesday. The stock has a market cap of $1.31 billion, a PE ratio of -12.15 and a beta of 0.23. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The firm has a fifty day moving average price of $5.06 and a 200-day moving average price of $3.64. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65. </p><p>Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). </p><h2>Institutional Investors Weigh In On Savara</h2><p>Large investors have recently bought and sold shares of the business. F m Investments LLC lifted its position in  Savara by 41.2% during the second quarter. F m Investments LLC now owns 314,846 shares of the company's stock valued at $718,000 after purchasing an additional 91,830 shares during the last quarter.  Farther Finance Advisors LLC lifted its holdings in shares of  Savara by 17.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company's stock valued at $87,000 after acquiring an additional 5,687 shares during the last quarter.  Emerald Advisers LLC lifted its holdings in shares of  Savara by 14.4% in the 2nd quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company's stock valued at $8,058,000 after acquiring an additional 444,155 shares during the last quarter.  Geode Capital Management LLC grew its position in  Savara by 5.2% in the second quarter. Geode Capital Management LLC now owns 2,970,183 shares of the company's stock worth $6,773,000 after acquiring an additional 147,946 shares in the last quarter.  Finally, Affinity Asset Advisors LLC bought a new stake in  Savara during the second quarter worth approximately $1,140,000. Institutional investors own  87.93% of the company's stock. </p><h2>About Savara</h2> (Get Free Report)<p>Savara Inc <span>NASDAQ: SVRA<span></span></span> is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.  </p><p>The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Savara</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>Trump’s “real estate deal for America” explained</li><li>Trump Did WHAT??</li><li>A month before the crash</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Savara Right Now?</h2><p>Before you consider Savara, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.</p><p>While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SVRA

<p>HC Wainwright has increased its FY2029 earnings per share estimate for Savara Inc. from $0.51 to $0.56, maintaining a "Buy" rating with a $10.00 target price. The stock has a consensus "Moderate Buy" rating with a $9.13 price target. Savara focuses on therapies for rare respiratory diseases, with its lead candidate under regulatory review. Institutional investors hold 87.93% of the stock.</p>

FY2029 Earnings Estimate for Savara Issued By HC Wainwright